BioCentury | Apr 12, 2019
Clinical News

Acceleron discontinues ACE-2494 due to antidrug antibodies

...Acceleron discontinued development of ACE-2494 due to the frequency of antidrug antibodies observed among healthy volunteers...
...trial. Acceleron Pharma Inc. (NASDAQ:XLRN) was developing ACE-2494 as a potential treatment of neuromuscular disorders. ACE-2494...
...Treatments” ). Targets: MSTN (GDF8) - Myostatin; GDF11 - Growth differentiation factor 11 Brian Moy, Assistant Editor ACE-2494 Acceleron...
BioCentury | Aug 31, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...1Q19. Acceleron Pharma Inc. (NASDAQ:XLRN) expects data next half from a Phase I trial of ACE-2494...
BioCentury | Aug 30, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...1Q19. Acceleron Pharma Inc. (NASDAQ:XLRN) expects data next half from a Phase I trial of ACE-2494...
BioCentury | Aug 1, 2018
Distillery Therapeutics

Cancer

...and hepatocellular carcinoma (HCC) and Phase I/II testing for pancreatic cancer. Acceleron Pharma Inc. has ACE-2494...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Musculoskeletal

...steps could include identifying and testing small molecule inhibitors of GDF11. Acceleron Pharma Inc. has ACE-2494...
BioCentury | Oct 5, 2015
Clinical News

Acceleron Pharma Inc preclinical data

...In mice, twice-weekly 10 mg/kg subcutaneous ACE-2494 increased muscle mass from baseline to week 4 by...
...controls (p?0.01 for all). Data were presented at the World Muscle Society meeting in Brighton. ACE-2494...
...GDF11) , activin A and activin B. Acceleron Pharma Inc . (NASDAQ:XLRN), Cambridge, Mass. Product: ACE-2494...
Items per page:
1 - 6 of 6